PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.98%
R&D growth 1.25-1.5x CRVO's 5.59%. Martin Whitman would scrutinize investment rationale.
58.15%
G&A growth above 1.5x CRVO's 37.03%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.40%
Operating expenses growth less than half of CRVO's 251.41%. David Dodd would verify sustainability.
20.40%
Total costs growth 1.25-1.5x CRVO's 15.98%. Martin Whitman would scrutinize control.
No Data
No Data available this quarter, please select a different quarter.
2.78%
D&A growth while CRVO reduces D&A. John Neff would investigate differences.
-20.82%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
97.30%
Other expenses growth while CRVO reduces costs. John Neff would investigate differences.
-19.78%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.78%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
12.20%
EPS growth while CRVO declines. John Neff would investigate advantages.
12.20%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
35.62%
Share count reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.
35.62%
Diluted share reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.